FrancophonIA/ELRC3.0 huggingface dataset:
English: When Lyxumia is used in combination with metformin alone, symptomatic hypoglycaemia occurred in 7.0% of lixisenatide patients and in 4.8% of placebo patients during the entire treatment period.
Maltese: Meta Lyxumia jintuża flimkien ma' metformin waħdu, kien hemm ipogliċemija sintomatika f'7.0% tal-pazjenti b'lixisenatide u 4.8% tal-pazjenti bi plaċebo matul il-perijodu kollu tal-kura.
English: Replace the pen cap.
Maltese: Inizjali ta' Kura.
English: • Cold (upper respiratory tract infection)
Maltese: • Ħorriqija (urtikarja) Rappurtar tal-effetti sekondarji
English: Table of activation and disposal In the table, write the date when you activated your pen and the date to throw it away 14 days later.
Maltese: Fit-tabella, ikteb id-data ta' meta attivajt il-pinna u d-data ta' meta trid tarmiha 14-il ġurnata wara.
English: In a study in healthy volunteers, a transient rise in heart rate has been observed after administration of lixisenatide 20 mcg.
Maltese: F'studju b'volontiera b'saħħithom, ġie osservat li wara l-għoti ta' lixisenatide 20 mcg kien hemm żieda momentanja fir-rata ta' tħabbit tal-qalb.
English: How to use Lyxumia
Maltese: X'fih Lyxumia
English: MARKETING AUTHORISATION NUMBER(S) EU/1/12/811/001 - 1 pen
Maltese: TAL-AWTORIZZAZZJONI GĦAT-TQEGĦID FIS-SUQ EU/1/12/811/001 pinna 1
English: During the entire treatment period, when Lyxumia was given with a sulphonylurea alone, symptomatic hypoglycaemia occurred in 22.7% of lixisenatide treated patients versus 15.2% with placebo (7.5% absolute difference).
Maltese: Matul il-perjodu kollu tal-kura, meta Lyxumia ngħata ma' xi sulphonylurea waħdu, l-ipogliċemija sintomatika seħħet fi 22.7% tal-pazjenti kkurati b'lixisenatide kontra 15.
English: Lyxumia given with a basal insulin alone, or with a combination of a basal insulin and metformin, or a combination of a basal insulin and a sulphonylurea resulted in statistically significant reductions in HbA1c and in 2-hour post-prandial glucose after a test- meal compared to placebo.
Maltese: Lyxumia mogħti ma' insulina bażilari waħdu, jew flimkien ma' insulina bażilari u metformin, jew flimkien ma' insulina bażilari u sulphonylurea wassal għal tnaqqis statistikament sinifikanti f'HbA1c u filglukosju ta' wara l-ikel wara sagħtejn wara ikla-test meta mqabbel ma' plaċebo.
English: Cystitis
Maltese: Quddiem
English: Methionine
Maltese: Skartoċċ
English: NAME OF THE MEDICINAL PRODUCT Lyxumia 10 micrograms solution for injection Lyxumia 20 micrograms solution for injection Lixisenatide
Maltese: Informazzjoni għall-utent Lyxumia 10 mikrogrammi soluzzjoni għall-injezzjoni Lyxumia 20 mikrogramma soluzzjoni għall-injezzjoni lixisenatide
English: Use is not recommended in patients with severe renal impairment or end-stage renal disease (see sections 4.2 and 5.2).
Maltese: L-użu mhuwiex irrakkomandat f'pazjenti b'indeboliment renali sever jew b'mard renali fl-aħħar stadju (ara sezzjonijiet 4.2 u 5.2).
English: LS change from baseline LS mean difference (SE) of lixisenatide versus 95% CI
Maltese: Bidla LS mil-linja bażi Differenza medja LS (SE) ta' lixisenatide kontra
English: There are no clinically relevant differences in the rate of absorption when lixisenatide is administered subcutaneously in the abdomen, thigh, or arm.
Maltese: M'hemm l-ebda differenzi klinikament rilevanti fir-rata ta' assorbiment meta lixisenatide ngħata taħt il-ġilda fl-addome, fil-koxxa, jew fid-driegħ.
English: The treatment initiation pack contains one green pen of Lyxumia 10 micrograms solution for injection and one purple pen of Lyxumia 20 micrograms solution for injection.
Maltese: Il-pakkett inizjali ta' kura fih pinna waħda ħadra ta' Lyxumia 10 mikrogrammi soluzzjoni għall-injezzjoni u pinna waħda vjola ta' Lyxumia 20 mikrogramma soluzzjoni għall-injezzjoni.
English: Basal insulin as background therapy Alone or in combination with a sulphonylurea *
Maltese: Insulina bażilari bħala terapija eżistenti waħedha jew flimkien ma' sulphonylurea*
English: Mean HbA1c (%) Baseline LS mean change from baseline Patients (%) achieving HbA1c <7.0% Mean duration of treatment with basal insulin at baseline (years) Mean change in basal insulin dose (U) Baseline LS mean change from baseline Mean body weight (kg) Baseline LS mean change from baseline *performed in Asian population
Maltese: Meta Lyxumia jiġi miżjud ma' terapija eżistenti ta' sulphonylurea jew ta' insulina bażilari, wieħed għandu jikkunsidra tnaqqis fid-doża tas-sulphonylurea jew tal-insulina bażilari biex jitnaqqas ir-riskju ta' ipogliċemija. Lyxumia m'għandux jingħata flimkien ma' insulina bażilari u xi sulphonylurea minħabba żżieda fir-riskju ta' ipogliċemija (ara sezzjoni 4.4).
English: Lyxumia 10 micrograms solution for injection
Maltese: Lyxumia 10 mikrogrammi soluzzjoni għall-injezzjoni
English: The Lyxumia Treatment Initiation pack includes two different coloured pens.
Maltese: Il-pakkett Inizjali ta'Kura ta' Lyxumia fih żewġ pinen b'kuluri differenti.
English: Lyxumia in combination with metformin, a sulphonylurea, pioglitazone or a combination of these agents showed statistically significant reductions in HbA1c, in fasting plasma glucose and in 2-hour post-prandial glucose after a test-meal compared to placebo at the end of the main 24-week treatment period (tables 2 and 3).
Maltese: Lyxumia flimkien ma' metformin, xi sulphonylurea, pioglitazone jew taħlita ta' dawn l-aġenti wera tnaqqis, li kien statistikament sinifikanti, fl-HbA1c, fil-glukosju tal-plażma waqt is-sawm u fil-glukosju ta'
English: Patients treated with lixisenatide should be advised of the potential risk of dehydration in relation to gastrointestinal adverse reactions and take precautions to avoid fluid depletion.
Maltese: Pazjenti li qed jieħdu lixisenatide għandhom jiġu avżati dwar ir-riskju potenzjali ta' deidrazzjoni minħabba r-reazzjonijiet avversi gastrointestinali u għandhom jieħdu prekawzjonijiet biex jevitaw nuqqas ta' fluwidu.
English: Animal studies did not indicate direct harmful effects with respect to male and female fertility in rats.
Maltese: Studji fl-annimali ma jurux effetti diretti ta' ħsara fuq il-fertilità maskili u femminili fil-firien.
English: Table 1: Adverse reactions reported in placebo- and active-controlled phase III studies during the entire treatment period (including the period beyond the main 24-week treatment period in studies with ≥76 weeks of total treatment).
Maltese: Tabella 1: Reazzjonijiet avversi rrapportati fi studji tat-Tielet Fażi bi li kienu jinkludu plaċebo jew il mediċina attiva matul il-perjodu kollu tal-kura (inkluż il-perjodu wara l-perjodu prinċipali ta' 24 ġimgħa ta' kura fi studji ta' ≥76 ġimgħa ta' trattament totali).
English: STATEMENT OF ACTIVE SUBSTANCE(S) Each dose (0.2 ml) contains 10 or 20 micrograms lixisenatide.
Maltese: Kull doża (0.2 ml) fiha 10 jew 20 mikrogramma lixisenatide
English: including 198 patients ≥75 years of age and 655 patients with moderate renal impairment).
Maltese: 5% irġiel u 52.5% nisa, u 517 kellhom ≥65 sena ta' età).
English: Morning (N= 255)
Maltese: (N= 570)
English: In the completed Phase III studies, it was observed that approximately 90% of the patients were able to remain on the once daily maintenance dose of 20 mcg Lyxumia at the end of the main 24-week treatment period.
Maltese: Fl-istudji lesti tat-Tielet Fażi, ġie osservat li madwar 90% tal-popolazzjoni tal-pazjenti kienu kapaċi jibqgħu fuq doża ta' manteniment ta' 20 mcg Lyxumia ta' darba kuljum fl-aħħar tal-perijodu prinċipali ta'
English: Lyxumia 20 micrograms solution for injection
Maltese: Lyxumia 20 mikrogramm soluzzjoni għall-injezzjoni
English: Use of purple 20 micrograms pen
Maltese: L-attivazzjoni tal-pinna l-vjola ta' 20 mikrogramma
English: Darunavir Mylan is available as tablets (75, 150, 300, 400, 600 and 800 mg).
Maltese: Darunavir Mylan jiġi f'pilloli (75, 150, 300, 400, 600 u 800 mg).
English: The full EPAR for Darunavir Mylan can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Maltese: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: Darunavir Mylan is a ‘generic medicine'.
Maltese: Darunavir Mylan huwa ‘mediċina ġenerika'.
English: Darunavir Mylan is an antiviral medicine used with other HIV medicines to treat patients with human immunodeficiency virus type 1 (HIV-1), a virus that causes acquired immune deficiency syndrome (AIDS).
Maltese: Darunavir Mylan huwa mediċina antivirali li tintuża f'kombinazzjoni ma' mediċini oħra tal-HIV fil-kura ta' pazjenti infettati bil-virus tal-immunodefiċjenza umana tat-tip 1 (HIV-1), virus li jikkawża ssindromu tal-immunodefiċjenza akkwiżita (AIDS).
English: The active substance in Darunavir Mylan, darunavir, is a protease inhibitor.
Maltese: Is-sustanza attiva f'Darunavir Mylan, id-darunavir, hija inibitur tal-proteażi.
English: This is a summary of the European public assessment report (EPAR) for Darunavir Mylan.
Maltese: Dan huwa sommarju tar-rapport pubbliku Ewropew ta' valutazzjoni (EPAR) għal Darunavir Mylan.
English: Darunavir Mylan darunavir
Maltese: Kif jintuża Darunavir Mylan?
English: Darunavir Mylan may be given to adults or children from 3 years of age and weighing at least 15 kg.
Maltese: Darunavir Mylan jista' jingħata lill-adulti u lit-tfal minn 3 snin 'il fuq u li jiżnu mill-inqas 15-il kg.
English: Other information about Darunavir Mylan
Maltese: Informazzjoni oħra dwar Darunavir Mylan
English: For adults who have not been treated before, the recommended dose is 800 mg once a day.
Maltese: Għall-adulti li ma jkunux ġew ikkurati qabel, id-doża rakkomandata hija 800 mg darba kuljum.
English: Because Darunavir Mylan is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's.
Maltese: Minħabba li Darunavir Mylan huwa mediċina ġenerika u bijoekwivalenti għall-mediċina ta' referenza, ilbenefiċċji u r-riskji tiegħu jitqiesu l-istess bħal dawk tal-mediċina ta' referenza.
English: Why is Darunavir Mylan approved?
Maltese: Għaliex ġie approvat Darunavir Mylan?
English: Studies on the benefits and risks of the active substance in the approved use have already been carried out with the reference medicine, Prezista, and do not need to be repeated for Darunavir Mylan.
Maltese: Diġà saru l-istudji fuq il-benefiċċji u r-riskji tas-sustanza attiva fl-użu approvat mal-mediċina ta' referenza, Prezista, u mhemmx għalfejn jiġu ripetuti għal Darunavir Mylan.
English: For adults who have been treated before, the dose is 600 mg twice a day.
Maltese: Għalladulti li jkunu ġew ikkurati qabel, id-doża hija 600 mg darbtejn kuljum.
English: The medicine is always taken either with cobicistat (in adults) or with low-dose ritonavir (in adults and children) and with other HIV medicines, and should be taken with food.
Maltese: Din il-mediċina tittieħed dejjem jew mal-kobikistat (fl-adulti) jew ma' doża baxxa ta' ritonavir (fl-adulti u fit-tfal) u ma' mediċini oħra talHIV, u għandha tittieħed mal-ikel.
English: What are the benefits and risks of Darunavir Mylan?
Maltese: X'inhuma l-benefiċċji u r-riskji ta' Darunavir Mylan?
English: For previously treated children the usually recommended dose varies between 375 and 600 mg twice a day depending on their weight.
Maltese: Fit-tfal li kienu diġà rċevew kura qabel, id-doża ġenerali rakkomandata tvarja bejn 375 u 600 mg darbtejn kuljum li tvarja skont il-piż tagħhom.
English: The Agency's Committee for Medicinal Products for Human Use (CHMP) concluded that, in accordance with EU requirements, Darunavir Mylan has been shown to have comparable quality and to be bioequivalent to Prezista.
Maltese: Il-Kumitat għall-Prodotti Mediċinali għall-Użu mill-Bniedem (CHMP) tal-Aġenzija kkonkluda li, b'mod konformi mar-rekwiżiti tal-UE, Darunavir Mylan wera li għandu kwalità komparabbli u huwa bijoekwivlenti għal Prezista.
English: For children aged 3 to 17 years and weighing at least 15 kg who have not be treated before, the recommended dose varies between 600 and 800 mg once daily depending on their weight.
Maltese: Fit-tfal ta' bejn it-3 snin u s-17-il sena u li jiżnu mill-inqas 15-il kg u li qatt ma ġew ikkurati qabel, iddoża rakkomandata tvarja bejn 600 u 800 mg darba kuljum skont il-piż tagħhom.
English: The Committee recommended that Darunavir Mylan be approved for use in the EU.
Maltese: Il-Kumitat irrakkomanda li Darunavir Mylan ikun approvat għall-użu fl-UE.
English: This means that Darunavir Mylan contains the same active substance and works in the same way as a ‘reference medicine' already authorised in the European Union (EU) called Prezista.
Maltese: Dan ifisser li Darunavir Mylan fiha l-istess sustanza attiva u jaħdem bl-istess mod bħall-"mediċina ta' referenza" li hija diġà awtorizzata fl-Unjoni Ewropea (EU) blisem ta' Prezista.
English: Darunavir Mylan can only be obtained with a prescription and treatment should be started by a healthcare professional who has experience in the management of HIV infection.
Maltese: Darunavir Mylan jista' jinkiseb biss b'riċetta ta' tabib u l-kura għandha tinbeda minn professjonist filqasam tas-saħħa li għandu esperjenza fil-ġestjoni tal-infezzjoni tal-HIV.
English: How does Darunavir Mylan work?
Maltese: Kif jaħdem Darunavir Mylan?
English: Warfarin - Calciphylaxis (EPITT no 18545)
Maltese: Warfarina - Kalċifilassi (EPITT no 18545)
English: • Severe diarrhoea
Maltese: • Dijarea severa
English: Natalizumab - Necrotising retinitis (EPITT no 18605)
Maltese: Natalizumab - Retinite nekrotika (EPITT no 18605)
English: Adopted at the 10-13 May 2016 PRAC
Maltese: Adottati fil-PRAC ta' bejn il-10-13 ta' Mejju 2016
English: Acute retinal necrosis (ARN) is a rare fulminant viral infection of the retina caused by the family of herpes viruses (e.g. varicella zoster).
Maltese: In-nekrożi tar-retina akuta (ARN) hija infezzjoni virali fulminanti rari tar-retina kkawżata mill-familja tal-virusis tal-herpes (eż. varicella zoster).
English: ARN has been observed in patients being administered TYSABRI and can be potentially blinding.
Maltese: ARN ġiet osservata f'pazjenti li ngħataw TYSABRI u tista' potenzjalment twassal għall-għama.
English: Section 4.4 - Special warnings and precautions for use Infections including other opportunistic infections
Maltese: Sezzjoni 4.4 - Twissijiet speċjali u prekawzjonijiet għall-użu Infezzjonijiet inkluż infezzjonijiet opportunistiċi oħra
English: Section 4.8 - Undesirable effects Skin and subcutaneous tissue disorders Frequency ‘not known': Calciphylaxis
Maltese: Sezzjoni 4.8 - Effetti mhux mixtieqa Disturbi fil-ġilda u fit-tessuti ta' taħt il-ġilda Frekwenza 'mhux magħrufa':
English: The condition is mainly observed in patients with end-stage renal disease on dialysis or in patients with known risk factors such as protein C or S deficiency, hyperphosphataemia, hypercalcaemia or hypoalbuminaemia.
Maltese: Il-kondizzjoni hija osservata l-aktar f'pazjenti b'mard renali fi stat terminali fuq dijaliżi jew f'pazjenti b'fatturi ta' riskju magħrufa bħal nuqqas fil-proteina Ċ jew S, iperfosfatemija, iperkalċemija jew ipoalbuminemija.
English: Some cases have occurred in patients with central nervous system (CNS) herpes infections (e.g. herpes meningitis and encephalitis).
Maltese: Xi każijiet seħħew f'pazjenti b'infezzjonijiet tal-herpes (eż. herpes meninġite u enċefalite) tas-sistema nervuża ċentrali (CNS).
English: • Impaired vision • Pain or redness of the eye(s)
Maltese: • Indeboliment fil-vista
English: Calciphylaxis is a rare syndrome of vascular calcification with cutaneous necrosis, associated with high mortality.
Maltese: Kalċifilassi hija sindromu rari ta' kalċifikazzjoni vaskulari b'nekrożi fil-ġilda, assoċjata ma' mortalità għolja.
English: […] If herpes encephalitis or meningitis occurs, TYSABRI should be discontinued and appropriate treatment for herpes encephalitis or meningitis should be administered.
Maltese: […] Jekk iseħħu herpes enċefalite jew meninġite, TYSABRI għandu jitwaqqaf, u għandha tingħata kura xierqa għal herpes enċefalite jew meninġite.
English: The treatment reported in these cases included antiviral therapy and in some cases, surgery (see section 4.4).
Maltese: Il-kura rrapportata f'dawn il-każijiet kienet tinkludi terapija antivirali u f'xi każijiet, kirurġija (ara sezzjoni 4.4).
English: A painful skin rash.
Maltese: Raxx tal-ġilda li jikkawża wġigħ.
English: On rare occasions warfarin can cause serious skin conditions, including one called calciphylaxis that can start with a painful skin rash but can lead to other serious complications.
Maltese: F'każijiet rari il-warfarina tista' tikkawża kondizzjonijiet serji fil-ġilda, inkluża waħda li tissejjaħ kalċifilassi li tista' tibda b'raxx tal-ġilda li jikkawża wġigħ iżda li jista' jwassal għal komplikazzjonijiet serji oħra.
English: Patients presenting with eye symptoms such as decreased visual acuity, redness and painful eye should be referred for retinal screening for ARN.
Maltese: Pazjenti li kellhom sintomi f'għajnejhom bħal tnaqqis fl-akutezza tal-vista, ħmura u wġigħ fl-għajn għandhom ikunu rreferiti għal skrining tar-retina għall-ARN.
English: 5 ml (50 mg/ml) 2 pre-filled syringes + 2 safety needles
Maltese: 2 siringi diġa' mimlija + 2 safety needles
English: 5 ml (50 mg/ml) 1 pre-filled syringe + 1 safety needle
Maltese: Siringa diġa' mimlija + 1 safety needle
English: MA (EU) number
Maltese: Numru tal-MA (ta' lEU)
English: 20ml (10 doses)
Maltese: Tiżmim20ml (10 dożi)
English: Packaging Content Package size
Maltese: Ippakkjar Kontenut Daqs ta' lIppakkjar
English: • Type 1 diabetes (C-peptide negative)
Maltese: • Dijabete Tip 1 (C-peptajd negattiv)
English: +ATP channels.
Maltese: +ATP.
English: - Anabolic hormones (e.g. methandrostenolone).
Maltese: - Ormoni Anaboliċi (eż. methandrostenolone).
English: Approximately 75% of the administered [
Maltese: Madwar 75 % ta' [
English: Diuretics, corticosteroids, beta2 agonists, somatropin, somatostatin analogues, rifampin, phenytoin and St. John's Wort (Hypericum perforatum)
Maltese: Dijuretiċi, kortikosterojdi, agonisti beta2, somatropin, analogi ta' somatostatin, rifampin, phenytoin u St John's Wort (Hypericum perforatum)
English: Packs contain 12, 24, 30, 60, 84, 120 and 360 tablets.
Maltese: Pakketti li fihom 12, 24, 30, 60, 84, 120 u 360 pillola.
English: CYP2C9 and CYP3A4 substrates
Maltese: Sottostrati ta' CYP2C9 u CYP3A4
English: What Starlix contains - The active substance is nateglinide.
Maltese: X'fih Starlix - Is-sustanza attiva hi nateglinide.
English: - Somatropin (a growth hormone).
Maltese: - Somatropin (ormon tat-tkabbir).
English: Combination with ACE-inhibitors, NSAIDs, salicylates, monoamine oxidase inhibitors, non-selective beta-adrenergic-blocking agents and anabolic hormones
Maltese: Kombinazzjoni ma' inibituri ACE, NSAIDs, saliċilati, inibituri ta' monoamine oxidase, aġenti mblukkaturi beta-adrenerġiċi mhux selettivi u ormoni anaboliċi
English: Frequencies are defined as: very common (1/10); common (1/100 to <1/10); uncommon (1/1,000 to <1/100); rare (1/10,000 to <1/1,000); very rare (<1/10,000); not known (cannot be estimated from the available data).
Maltese: Il-frekwenzi huma definiti bħala: komuni ħafna (1/10); komuni (1/100 sa <1/10); mhux komuni (1/1,000 sa <1/100); rari (1/10,000 sa <1/1,000); rari ħafna (<1/10,000); mhux magħruf (ma tistax tittieħed stima mid-data disponibbli).
English: - St. John's Wort, also known as Hypericum perforatum (a herbal medicine).
Maltese: John's Wort (Hypericum perforatum).
English: - Monoamine oxidase inhibitors (used to treat depression).
Maltese: - Inibituri ta' monoamine oxidase (użati fil-kura tad-depressjoni).
English: Date of first authorisation: 03 April 2001 Date of latest renewal: 24 April 2006
Maltese: Data tal-ewwel awtorizzazzjoni: 03 April 2001 Data tal-aħħar tiġdid: 24
English: Starlix contains lactose monohydrate.
Maltese: Starlix fih lactose monohydrate.
English: In completed clinical trials, symptoms of hypoglycaemia were reported in 10.4% with nateglinide monotherapy, 14.5% with nateglinide+metformin combination, 6.9% with metformin alone, 19.8% with glibenclamide alone, and 4.1% with placebo.
Maltese: Fi provi kliniċi li ntemmu, sintomi ta' ipogliċemija kienu irrapurtati f'10.4 % b'monoterapija b'nateglinide, 14.5 % b'taħlita ta' nateglinide+metformin, 6.9 % b'metformin waħdu, 19.8 % b'glibenclamide waħdu, u 4.1 % bilplaċebo.
English: - Rifampin (used, for example, to treat tuberculosis).
Maltese: - Rifampin (użat, ngħidu aħna, biex jittratta t-tuberkolożi).
English: Oral antidiabetics, including Starlix, may also produce symptoms of hypoglycaemia.
Maltese: L-antidijabetiċi orali, inkluż Starlix, jistgħu anke jikkawżaw sintomi ta' ipogliċemija.
English: - Beta blockers or ACE inhibitors (angiotensin-converting enzyme inhibitors) (used, for example,
Maltese: - Imblokkaturi beta jew inibituri ACE (impedituri ta' l-enżimi li jikkonvertu l'angiotensin) (użati,
English: - Salicylates such as aspirin (used as painkillers).
Maltese: - Saliċilati bħall-aspirina (użati bħala analġeżiċi).
English: Interaction studies with a CYP3A4 inhibitor have not been carried out in vivo.
Maltese: Studji ta' interazzjoni b' impeditur CYP3A4 in vivo ma sarux.
English: - Somatostatin analogues such as lanreotide and octreotide (used to treat acromegaly).
Maltese: - Somatostatin analogues bħal lanreotide u octreotide (użati biex jittrattaw akromegalija).
English: • Severe hepatic impairment
Maltese: • Impediment epatiku sever
English: The following agents may reduce the hypoglycaemic effect of nateglinide: diuretics, corticosteroids, beta2 agonists, somatropin, somatostatin analogues (e.g. lanreotide, octreotide), rifampin, phenytoin and St. John's Wort (Hypericum perforatum).
Maltese: Dawn l-aġenti li jmiss jistgħu jnaqqsu l-effett ipogliċemiku ta' nateglinide: dijuretiċi, kortikosterojdi, agonisti beta2, somatropin, somatostatin analogues (eż. lanreotide, octreotide), rifampin, phenytoin u St.
English: Approximately 6-16% of the administered dose was excreted in the urine as unchanged drug.
Maltese: Madwar 6-16 % tad-doża li ngħatat kienet imneħħija fl-awrina bħala mediċina mhux mibdula.
English: Excipient with known effect Lactose monohydrate: 141.5 mg per tablet.
Maltese: Eċċipjent b'effett magħruf Lactose monohydrate: 141.5 mg għal kull pillola.
English: Each tablet contains 60, 120 or 180 mg nateglinide.
Maltese: Kull pillola fiha 60, 120 jew 180 mg nateglinide.
English: Starlix contains lactose
Maltese: Starlix fih lactoce
English: Elderly The clinical experience in patients over 75 years of age is limited.
Maltese: L-esperjenza klinika f'pazjenti minn 75 sena 'l fuq hija limitata.
English: Blisters: PVC/PE/PVDC blisters, backed with a heat-sealable lacquered aluminium foil.
Maltese: Folji tal-PVC/PE/PVDC mgħottija minn wara b'fojl tal-aluminju bil-laker u li jista' jiġi ssiġillat bis-sħana.
English: Tmax was independent of dose.
Maltese: It-Tmax kienet indipendenti mid-doża.
English: Starlix with food, drink and alcohol
Maltese: Starlix ma' ikel, xorb u alkoħol
English: The following agents may enhance the hypoglycaemic effect of nateglinide: angiotensin-converting enzyme inhibitors (ACEI), non-steroidal anti-inflammatory agents, salicylates, monoamine oxidase inhibitors, non-selective beta-adrenergic-blocking agents and anabolic hormones (e.g. methandrostenolone).
Maltese: Dawn l-aġenti li jmiss jistgħu iżidu l-effett ipogliċemiku ta' nateglinide: impedituri ta' l-enzima talkonverżjoni ta' angiotensin (ACEI), aġenti antiinfjammatorji mhux sterojdi, saliċilati, inibituri talmonoamino ossidasi, aġenti mblukkaturi beta-adrenerġiċi mhux selettivi u ormoni anaboliċi (eż. methandrostenolone).
English: Excipient with known effect Lactose monohydrate: 283 mg per tablet.
Maltese: Eċċipjent b'effett magħruf Lactose monohydrate: 283 mg għal kull pillola.
English: Excipient with known effect Lactose monohydrate: 214 mg per tablet.
Maltese: Eċċipjent b'effett magħruf Lactose monohydrate: 214 mg għal kull pillola.
English: What Starlix is The active substance of Starlix, nateglinide, belongs to a group of medicines called oral antidiabetics.
Maltese: Is-sustanza attiva ta' Starlix, nateglinide, jagħmel parti minn grupp ta' mediċini msejħa antibjotiċi orali.